| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate |
2004-09-23^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8c8e888b2dee85226bc8a760dd1f06a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_966ee9d1cba826d892e4452798f178c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a8bb3434d4d08fabc214fd59113298d |
| publicationDate |
2005-05-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005113405-A1 |
| titleOfInvention |
Methods of treating rheumatoid arthritis using NF-kB inhibitors |
| abstract |
The present invention concerns a method of treating rheumatoid arthritis by diagnosing that a person is in need of treatment for rheumatoid arthritis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain embodiments, the administration is with a substantial absence of uterotropic activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7378427-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019139965-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7304073-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006111421-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006025436-A1 |
| priorityDate |
2003-09-24^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |